George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.925
Bid: 18.40
Ask: 19.45
Change: -0.275 (-1.43%)
Spread: 1.05 (5.707%)
Open: 19.20
High: 0.00
Low: 0.00
Prev. Close: 19.20
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ADOR Diagnostics secures $7.5m investment

23 Oct 2023 07:00

RNS Number : 8845Q
BATM Advanced Communications Ld
23 October 2023
 

LEI: 213800FLQUB9J289RU66

23 October 2023

BATM Advanced Communications Limited

("BATM" or the "Group")

 

ADOR Diagnostics secures $7.5m investment

 

BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, announces that ADOR Diagnostics Ltd ("ADOR"), an associate company of the Group, has secured an investment of $7.5m, of which the Group is contributing $3.5m. Half of the investment is being made on the signing of the investment agreement and the remainder will be paid on the completion of milestones over the next six months. Following this investment, the Group's shareholding in ADOR will increase to 43.6%.

 

ADOR, a disruptive molecular diagnostics company, is developing the advanced NATlab molecular biology platform that uses a novel isothermal rolling circle amplification method for syndromic multiplex diagnostics, with a focus on infectious disease. This sample-to-answer solution is designed to provide rapid and accurate results, enabling exact pathogen detection and timely treatment. R&D continues to progress and pre-clinical trials are underway with a hospital. With 11 patents issued in the US and 8 internationally with others pending, the Group expects the total addressable market for NATlab to grow to $15.8bn by 2025.

 

Moti Nagar, CEO of BATM, said: "We are very excited about the groundbreaking potential of ADOR, which has a technology that is set to truly disrupt the molecular diagnostics market - and is backed by a strong and growing international patent portfolio. This investment, supported by our vast experience of transforming IP into market-ready products, will advance the development of ADOR towards what we believe will be a significant value creation opportunity for BATM. We look forward to reporting on ADOR's progress."

 

 

Enquiries

 

BATM Advanced Communications

Moti Nagar, Chief Executive Officer

+972 9866 2525

Ran Noy, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

+44 20 7408 4050 

Gracechurch Group

Harry Chathli, Claire Norbury

+44 20 4582 3500

 

Forward-looking statements  

 

This document contains forward-looking statements. Those statements reflect the current opinions, evaluations and estimations of the Group's management, and are based on the current data regarding the Group's business as is detailed in this document and in the Group's periodical, interim and immediate reports. The Group does not undertake any obligation or make any representation that actual results and events will be in line with those statements, and stresses that they may differ materially from those statements, due to changes in the Group's business, market, competition, demand for the Group's products or services, general economic factors or other factors that can influence the Group's business and results, due to the risk factors that are detailed in the Group's Annual Report, and due to information and factors that are currently unknown to the Group's management and that, if known, would affect the management's opinions, evaluations or estimations. The Group will report the actual results and events according to its legal, accounting and regulatory obligations, and does not undertake any other obligation to report them or their deviations from the forward-looking statements, or to update any of the forward-looking statements in this document or to report that it is not valid anymore. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEANEAADFDFFA
Date   Source Headline
18th Apr 20247:00 amRNSBATM to deliver Edgility to new Tier 1 customer
8th Apr 20247:00 amRNSBATM awarded new Edgility contract from Cemex
3rd Apr 20247:00 amRNSAnnual Financial Report
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review
14th Apr 20229:30 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.